Product Name:
NDR1-pS281+pT282
Product Number:
ab-pk731
Target Full Name: Serine/threonine-protein kinase 38
Target Alias: AA617404; DJ108K11.2; NDR1 protein kinase; NDR; STK38; CCDS4822.1; ENSG00000112079
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK731
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S281+T282
Protein UniProt: Q15208
Protein SigNET: Q15208
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human NDR1 (NDR, STK38) sequence peptide Cat. No.: PE-04AOD99
Antibody Immunogen Sequence: LAF(pS)(pT)VGT(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues L278 to T285; In the protein kinase catalytic domain activation T loop region between subdomains VII and VIII.
Production Method: Corresponds to amino acid residues L278 to T285; In the protein kinase catalytic domain activation T loop region between subdomains VII and VIII.
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Medium immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 52-57 kDa.
Related Product 1: NDR1-pS281+pT282 blocking peptide
Scientific Background: NDR1 (STK38) is a protein-serine/threonine kinase of the AGC group and NDR family. It is activated by binding of S100B, which releases autoinhibitory N-lobe interactions, enabling ATP to bind and the autophosphorylation of S281. Phosphorylation at S281 increases phosphotransferase activity and interaction with MOBP. T444 then undergoes calcium-dependent phosphorylation by an upstream kinase. Interactions between phosphorylated T444 and the N-lobe promote additional structural changes that complete the activation of the kinase. Phosphorylation at T74 induces interaction with S100B. T444 then undergoes calcium-dependent phosphorylation by an upstream kinase. T74A, K118A, S281A, and T444A mutations are involved in decreased or loss of autophosphorylation and kinase activity. NDR1 is a negative regulator of MAP3K1/2 signalling. It converts MAP3K2 from its phosphorylated form to its nonphosphorylated form and inhibits autophosphorylation of MAP3K2. NDR1 is an important regulator of Myc's oncogenic activity in human B-cell lymphomas. It also regulates G/S cell cycle transition. The MAPK/ERK pathway has been implicated in oncogenesis as either a promoter or inhibitor depending on the cancer system.
